{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T18:12:12Z","timestamp":1779300732287,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bulcan.2026.01.027","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:16:08Z","timestamp":1773231368000},"page":"790-801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Strat\u00e9gies de d\u00e9sescalade th\u00e9rapeutique dans l\u2019usage des anti-PD1\u00a0et anti-PD-L1\u00a0: doses, fr\u00e9quences et dur\u00e9es"],"prefix":"10.1016","volume":"113","author":[{"given":"Lila","family":"Philipps","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9o","family":"Mas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Samaille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Blanchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bulcan.2026.01.027_bib0275","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.bulcan.2026.01.027_bib546","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.bulcan.2026.01.027_bib0285","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1\u00a0tumor proportion score\u226550","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2026.01.027_bib0290","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.bulcan.2026.01.027_bib0295","first-page":"4056","article-title":"Pembrolizumab in advanced urothelial carcinoma: results of KEYNOTE-045\u00a0and KEYNOTE-052\u00a0after up to 5\u00a0years","volume":"41","author":"Bellmunt","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.bulcan.2026.01.027_bib0300","first-page":"1943","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177\u00a0study","volume":"43","author":"Andr\u00e9","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.01.027_bib0305","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab","volume":"23","author":"Malmberg","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.01.027_bib0310","series-title":"Keytruda (pembrolizumab)\u00a0\u2013\u00a0avis \u00e9conomique","year":"2023"},{"key":"10.1016\/j.bulcan.2026.01.027_bib0315","series-title":"Les m\u00e9dicaments et dispositifs m\u00e9dicaux on\u00e9reux","year":"2025"},{"key":"10.1016\/j.bulcan.2026.01.027_bib0320","series-title":"KEYTRUDA\u00ae (pembrolizumab)\u00a0\u2013\u00a0financial support & pricing information","year":"2025"},{"issue":"4","key":"10.1016\/j.bulcan.2026.01.027_bib0425","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.annonc.2022.01.003","article-title":"Improving access to immunotherapy in low- and middle-income countries","volume":"33","author":"Patel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.01.027_bib0330","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3332\/ecancer.2022.1464","article-title":"Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India","volume":"16","author":"Patil","year":"2022","journal-title":"ecancermedicalscience"},{"key":"10.1016\/j.bulcan.2026.01.027_bib0335","first-page":"1","article-title":"Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy?","volume":"5","author":"Renner","year":"2019","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.bulcan.2026.01.027_bib0340","doi-asserted-by":"crossref","first-page":"906251","DOI":"10.3389\/fonc.2022.906251","article-title":"Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"issue":"no 3","key":"10.1016\/j.bulcan.2026.01.027_bib547","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.23.00236","article-title":"\u00ab\u202fStandard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)\u202f\u00bb","volume":"42","author":"Vasudev","year":"2024","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.bulcan.2026.01.027_bib0345","series-title":"Health care's climate footprint: how the health sector contributes to the global climate crisis and opportunities for action","year":"2019"},{"key":"10.1016\/j.bulcan.2026.01.027_bib0350","series-title":"Feuille de route\u2013planification \u00e9cologique du syst\u00e8me de sant\u00e9","year":"2023"},{"issue":"11","key":"10.1016\/j.bulcan.2026.01.027_bib0355","doi-asserted-by":"crossref","first-page":"e915","DOI":"10.1016\/S2542-5196(24)00245-6","article-title":"Effect of alternative dosing strategies of pembrolizumab and nivolumab on health-care emissions in the Netherlands: a carbon footprint analysis","volume":"8","author":"Malmberg","year":"2024","journal-title":"Lancet Planet Health"},{"issue":"28","key":"10.1016\/j.bulcan.2026.01.027_bib0280","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001\u00a0study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.01.027_bib0360","doi-asserted-by":"crossref","first-page":"e00757","DOI":"10.1002\/prp2.757","article-title":"Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology","volume":"9","author":"Chatelut","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"10.1016\/j.bulcan.2026.01.027_bib0365","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/19420862.2015.1136043","article-title":"Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1\u00a0monoclonal antibody, an immune checkpoint inhibitor","volume":"8","author":"Deng","year":"2016","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.bulcan.2026.01.027_bib0370","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3390\/vaccines8040730","article-title":"Budget impact analysis of fixed dose versus weight-based dosing regimen of nivolumab and pembrolizumab in the treatment of non-small cell lung cancer","volume":"8","author":"Monirul","year":"2020","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.bulcan.2026.01.027_bib0375","doi-asserted-by":"crossref","first-page":"djx062","DOI":"10.1093\/jnci\/djx063","article-title":"A pharmacoeconomic analysis of personalized versus fixed dosing of pembrolizumab in first-line PD-L1-positive non-small-cell lung cancer","volume":"109","author":"Goldstein","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2026.01.027_bib0380","series-title":"Nivolumab (Opdivo) for adjuvant treatment of resected esophageal or gastroesophageal junction cancer. CADTH reimbursement review","article-title":"Table 2. Implementation guidance from pERC","year":"2022"},{"issue":"7","key":"10.1016\/j.bulcan.2026.01.027_bib0385","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1377\/hlthaff.2023.00102","article-title":"Adopting weight-based dosing with pharmacy-level stewardship strategies could reduce cancer drug spending by millions","volume":"42","author":"Bryant","year":"2023","journal-title":"Health Aff"},{"issue":"5","key":"10.1016\/j.bulcan.2026.01.027_bib0390","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3390\/cancers14051157","article-title":"Comparative effectiveness and safety of standard-dose and low-dose pembrolizumab in patients with non-small-cell lung cancer: a multi-institutional cohort study in Taiwan","volume":"14","author":"Chang","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.027_bib0395","first-page":"101","article-title":"Efficacy of lower fixed dose pembrolizumab in the treatment of non-small cell lung cancer patients in a lower-middle income country: Jordan experience","volume":"2","author":"Abbasi","year":"2022","journal-title":"Ann Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2026.01.027_bib0400","doi-asserted-by":"crossref","first-page":"e000332","DOI":"10.1136\/esmoopen-2018-000332","article-title":"Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity","volume":"3","author":"Yoo","year":"2018","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.027_bib0405","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1186\/s12885-022-10271-6","article-title":"Low-dose nivolumab in advanced hepatocellular carcinoma","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.027_bib0410","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ijc.33534","article-title":"Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer","volume":"149","author":"Low","year":"2021","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2026.01.027_bib0415","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.3390\/ijerph19105999","article-title":"Modified-dose pembrolizumab and prognostic outcomes among non-small cell lung cancer patients: a chart review study","volume":"19","author":"To","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.027_bib0420","first-page":"59","article-title":"Low-dose nivolumab in renal cell carcinoma: a real-world experience","volume":"19","author":"Zhao","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.bulcan.2026.01.027_bib541","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.5009","article-title":"Phase I trial of nivolumab with dose-ranging in metastatic RCC","author":"Motzer","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"16_suppl","key":"10.1016\/j.bulcan.2026.01.027_bib0430","first-page":"508612","article-title":"Phase III randomized study comparing ultra-low dose immunotherapy to standard cytotoxic chemotherapy for solid tumors in second line and beyond setting (DELII: Development of Low dose Immunotherapy in India)","volume":"43","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl_7","key":"10.1016\/j.bulcan.2026.01.027_bib0435","doi-asserted-by":"crossref","first-page":"S1622","DOI":"10.1016\/j.annonc.2024.10.640","article-title":"Evaluation of low dose nivolumab with neoadjuvant chemotherapy in non-small cell lung cancer: a phase II open-label randomized clinical trial (ELON)","volume":"35","author":"Biswal","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.01.027_bib0440","doi-asserted-by":"crossref","first-page":"1274532","DOI":"10.3389\/fphar.2023.1274532","article-title":"Integrating treatment cost reduction strategies and biomarker research to reduce costs and personalize expensive treatments: an example of a self-funding trial in non-small cell lung cancer","volume":"14","author":"Buma","year":"2023","journal-title":"Front Pharmacol"},{"issue":"26","key":"10.1016\/j.bulcan.2026.01.027_bib0445","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1\u00a0antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2026.01.027_bib0450","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/annonc\/mdz037","article-title":"Model-informed drug development approach supporting approval of the 4-week dosing schedule for nivolumab across multiple indications: a regulatory perspective","volume":"30","author":"Bi","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.01.027_bib0455","doi-asserted-by":"crossref","first-page":"102070","DOI":"10.1016\/j.esmoop.2023.102070","article-title":"Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study","volume":"8","author":"Colard-Thomas","year":"2023","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.bulcan.2026.01.027_bib0460","doi-asserted-by":"crossref","first-page":"e230490","DOI":"10.1001\/jamanetworkopen.2023.0490","article-title":"Multinational analysis of estimated health care costs related to extended-interval fixed dosing of checkpoint inhibitors","volume":"6","author":"Goldstein","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.bulcan.2026.01.027_bib0465","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jcph.1984","article-title":"Pharmacokinetic simulation analysis of less frequent nivolumab and pembrolizumab dosing: pharmacoeconomic rationale for dose de-escalation","volume":"62","author":"Peer","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.bulcan.2026.01.027_bib0470","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41416-024-02659-x","article-title":"Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients","volume":"130","author":"Puszkiel","year":"2024","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.027_bib0475","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.027_bib542","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12885-023-10881-8","article-title":"A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study","volume":"23","author":"Gravis","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bulcan.2026.01.027_bib543","doi-asserted-by":"crossref","first-page":"106TiP","DOI":"10.1016\/j.esmoop.2024.102685","article-title":"106TiP PULSE: a non-inferiority study of maintenance pembrolizumab at usual or low dose in non-squamous lung cancer","volume":"9","author":"Masip","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.bulcan.2026.01.027_bib544","doi-asserted-by":"crossref","first-page":"107030","DOI":"10.1016\/j.cct.2022.107030","article-title":"REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers","volume":"124","author":"Merrick","year":"2023","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"10.1016\/j.bulcan.2026.01.027_bib545","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/S1470-2045(23)00095-5","article-title":"REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment","volume":"24","author":"Ghorani","year":"2023","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2026.01.027_bib0480","first-page":"1077","article-title":"Assessment of nivolumab benefit-risk profile of every 2-week versus every 4-week dosing schedule across multiple tumor types","volume":"32","author":"Zhao","year":"2021","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2026.01.027_bib0485","first-page":"21263","article-title":"Safety and efficacy of extended dosing intervals of immune checkpoint inhibitors in non-small cell lung cancer: a real-world study","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.bulcan.2026.01.027_bib0495","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","article-title":"Discontinuation of anti-PD-1\u00a0antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma","volume":"30","author":"Jansen","year":"2019","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.bulcan.2026.01.027_bib0500","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.19.01464","article-title":"Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1\u00a0blockade","volume":"38","author":"Betof Warner","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.01.027_bib556","doi-asserted-by":"crossref","first-page":"1524945","DOI":"10.3389\/fimmu.2025.1524945","article-title":"Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: a systematic review and meta-analysis","volume":"16","author":"Lallas","year":"2025","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.bulcan.2026.01.027_bib0515","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"issue":"10027","key":"10.1016\/j.bulcan.2026.01.027_bib555","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.bulcan.2026.01.027_bib554","doi-asserted-by":"crossref","first-page":"100970","DOI":"10.1016\/j.lanepe.2024.100970","article-title":"Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study","volume":"43","author":"Rousseau","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"33","key":"10.1016\/j.bulcan.2026.01.027_bib553","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2026.01.027_bib552","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00262-021-03114-z","article-title":"Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study","volume":"71","author":"Bilger","year":"2022","journal-title":"Cancer Immunol Immunother CII"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.027_bib551","first-page":"29","volume":"15","author":"Toffart","year":"2023","journal-title":"Rev Mal Respir Actual"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.027_bib550","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010424","article-title":"Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors","volume":"13","author":"Taieb","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2026.01.027_bib548","doi-asserted-by":"crossref","first-page":"102220","DOI":"10.1016\/j.esmoop.2023.102220","article-title":"Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis","volume":"9","author":"Landr\u00e9","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.bulcan.2026.01.027_bib549","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04181-w","article-title":"Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial","author":"Huang","year":"2026","journal-title":"Nat Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126001414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126001414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:57:46Z","timestamp":1779299866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126001414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0007455126001414"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.01.027","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strat\u00e9gies de d\u00e9sescalade th\u00e9rapeutique dans l\u2019usage des anti-PD1\u00a0et anti-PD-L1\u00a0: doses, fr\u00e9quences et dur\u00e9es","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}